profile

Prof Stephen Gillespie:
Sir James Black Chair of Medicine

Prof Stephen Gillespie

Prof Stephen Gillespie
Medical and Biological Sciences Building
University of St Andrews
North Haugh
St Andrews
KY16 9TF
Fife
UK

tel: 01334 461871
fax: 01334 473482
room: 212
email: shg3@st-andrews.ac.uk

Related Content:


Research Group Site

School of Medicine
Gillespie Research Group
Biomedical Sciences Research Complex
Evolution, Genes and Genomics Group
Institute for Data-Intensive Research
Medicine Infection Research Group

edit shg3 details


Stephen Gillespie has worked in Kenya researching the relationship between malaria and lower respiratory tract infection and the prevalence of parasitic infection in children in Kilifi, Kenya. He has investigated a cholera epidemic and vaccine failures in Guerrero, Mexico. He has been working in collaboration with colleagues at Kilimanjaro Christian Medical Centre since 1988 where he has, variously, studied respiratory and parasite diagnostics and novel antimalarials, anti-helminthics and anti tuberculosis agents. His main research activity is in the area of tuberculosis drug development.

For the last twenty five years Stephen Gillespie has been involved in various aspects of  tuberculosis diagnosis and drug development. This has included the evaluation of new candidate antituberculosis agents in vitro. This work has expanded into studies of the molecular mechanisms of resistance and the development of model systems to measure the fitness deficits found in resistant strains. He has been involved in the development of fluoroquinolones for tuberculosis having performed early bacterial activity studies and clinical trials of ciprofloxacin. More recently he has led the group working on the clinical development of moxifloxacin in collaboration with the Global Alliance for TB Drug Development as Chief Investigator of the REMox TB study. He later went on to be the coordinating investigator for the TB Alliance STAND trial (Shortening Treatment by Advancing New Drugs). He is also one of the Chief Investigators of the PanACEA consortium that links European and African research groups in enhancing anti-tuberculosis therapy.  

He has an extensive record of developing novel mirobiological diagnostics.  Most recently, he has developed SLIC (Scattered Light Integrating Collector),  which performs phenotypic antibiotic susceptibility testing in less than 30 minutes. This innovation recently won a Longitude Prize Discovery Award. In addition he has developed the Molecular Bacterial Load Assay, an innovative way of detecting, quantifiying and determining the viability of bacteria in a single test that allows both diagnosis and the monitoring of treatment response.

 



source: symbiosis


Recent Publications:

5 (of 275 /dk/atira/pure/researchoutput/status/published available) for shg3 (source: University of St Andrews PURE)
Please click title of any item for full details

A tuberculosis molecular bacterial load assay (TB-MBLA) Wilber Sabiiti, Khalide Azam, Katarina Orascova, Derek James Sloan, Stephen Henry Gillespie
Journal of Visualized Experiments 2020 vol. 158
Real-time monitoring of live mycobacteria with a microfluidic acoustic-Raman platform Mingzhou Chen, Bjorn Hammarstrom, Robert Hammond, Peter Glynne-Jones, Stephen Henry Gillespie, Kishan Dholakia
Communications Biology 2020 vol. 3
Using Machine Learning for Automatic Estimation of M. Smegmatis Cell Count from Fluorescence Microscopy Images Daniel Vente, Ognjen Arandjelović, Stephen Henry Gillespie
2020 pp. 57-68
Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations? Frank Kloprogge, Robert Hammond, Andrew Copas, Stephen Henry Gillespie, Oscar Della Pasqua
Journal of Antimicrobial Chemotherapy 2019 vol. 74 pp. 3530–3536
Heat-inactivation renders sputum safe and preserves Mycobacterium tuberculosis RNA for downstream molecular tests Wilber Sabiiti, Khalide Azam, Ezembro Esmeraldo, Nilesh Bhatt, Andrea Rachow, Stephen Henry Gillespie
Journal of Clinical Microbiology 2019 vol. 57